Last edition
News about "IDG Capital "
D3 Bio Secures USD 108 Million in Series B Financing to Advance Global Clinical Programmes
D3 Bio has raised USD 108 million in Series B financing to advance its global clinical programmes. The funds will support the Phase III pivotal trial of its lead asset, elisrasib (D3S-001), while also accelerating the development of the company’s broader pipeline of targeted and immuno-oncology therapies with first-in-class and best-in-class potential.
IDG Capital | 11/12/2025 | By Akanki
Bayer Launches Bayer Co.Lab AdVenture Platform in China
Bayer launches Co.Lab AdVenture to connect biotech startups with global VCs, accelerating early-stage innovation through its lifesciences incubator network.
IDG Capital | 11/09/2025 | By Dineshwori | 148
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy